NettetOur pipeline spans a full range of dosage forms, including orals, topicals, liquid, lyophilized and complex injectables. As a leader in oncology, Accord Healthcare constitutes a 30% volume share of major chemotherapy injectable molecules. Across all areas, our excellence in research is driven by 500 scientists involved in product development ... Nettet26. aug. 2024 · Every year, the company invests ~6-7% of its revenues in R&D. Currently; Intas has over 10,000 product registrations worldwide and a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars and ...
Accord Healthcare - Advancement. Agility. Accessibility.
NettetIntas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “biosimilars for billions” across niche segments such as oncology, … NettetIntas’ Biologics Business Unit was launched in 2000 with a focus on developing high-quality recombinant DNA protein (rDNA) products and plasma-derived products. Its … cs 放送を見る方法
Intas corporate ppt - SlideShare
NettetIndia has, by far, demonstrated the greatest acceptance of ‘similar biologics’. According to our research at GaBI Online, the first ‘similar biologic’ was approved and marketed in India for a hepatitis B vaccine in 2000. In recent years over 50 biopharmaceutical products have been approved for marketing in India, with more than half of ... NettetIntas Pharmaceuticals General Information. Description. Operator of a global pharmaceutical company intended to offer biopharmaceutical products and services. The company specializes in oncology products for solid tumors, hematological malignancies and supportive therapies and also offers products for critical disorders. NettetGlenmark India. To receive medical or safety information or to report a product complaint or side effect (also called an adverse event), please contact the Glenmark customer service center at: [email protected] or at. 18002666255 (toll free for India) or 022-4018-9999. from 9:00AM to 6:00PM IST (Monday to Friday) cs 放送を見るには